PedAM
Pediatric Disease Annotations & Medicines
| Disease | lung disease |
| Phenotype | C0020542|pulmonary hypertension |
| Sentences | 52 |
| PubMedID- 22221973 | pulmonary hypertension due to chronic lung disease: updated recommendations of the cologne consensus conference 2011. |
| PubMedID- 21719760 | Rationale: senescence of pulmonary artery smooth muscle cells (pa-smcs) caused by telomere shortening or oxidative stress may contribute to pulmonary hypertension associated with chronic lung diseases. |
| PubMedID- 20862620 | [pulmonary hypertension due to chronic lung disease. |
| PubMedID- 26283756 | Methods: one hundred thirty-four patients with clinically diagnosed interstitial lung diseases complicated by pulmonary hypertension underwent transthoracic lung sonography and doppler echocardiography for assessment of the presence of b-lines, the distance between them, and the pulmonary artery (pa) systolic pressure. |
| PubMedID- 26361668 | pulmonary hypertension (ph) associated with lung diseases not only is an index of poor outcome but also is an indication for bilateral procedure. |
| PubMedID- 26453478 | Purpose: recent imaging studies demonstrated the usefulness of quantitative computed tomographic (ct) analysis assessing pulmonary hypertension (ph) in patients with chronic obstructive lung disease (copd-ph). |
| PubMedID- 23271856 | We report a nigerian sickle cell patient who presented with computed tomography proven interstitial lung disease complicated by pulmonary hypertension and cor pulmonale. |
| PubMedID- 24671311 | Polysomnographic differences associated with pulmonary hypertension in patients with advanced lung disease due to cystic fibrosis. |
| PubMedID- 26029570 | We also present a review of the literature on treatment of pulmonary hypertension in patients with chronic lung disease. |
| PubMedID- 25613108 | Role of bnp and echo measurement for pulmonary hypertension recognition in patients with interstitial lung disease: an algorithm application model. |
| PubMedID- 26115628 | The treatment of choice for patients who are hypoxemic and have pulmonary hypertension associated with chronic lung disease is long-term oxygen therapy. |
| PubMedID- 25813769 | Background: pulmonary hypertension associated with lung disease (phld) has been shown to be a predictor of disease severity and survival in patients awaiting lung transplantation. |
| PubMedID- 22054725 | Response to pulmonary vasodilator treatment in a former smoker with combined interstitial lung disease complicated by pulmonary hypertension: case report and review of the literature. |
| PubMedID- 25076998 | pulmonary hypertension (ph) due to lung disease is a form of precapillary ph and is defined as mean pulmonary artery pressure (mpap) ≥25 mmhg associated with pulmonary artery wedge pressure (pawp) ≤15 mmhg and normal or reduced cardiac output (co). |
| PubMedID- 25954555 | Despite aggressive intervention, he continued to be ventilator dependent with worsening pulmonary hypertension due to chronic lung disease. |
| PubMedID- 20819757 | This article focuses on the recent advances in our knowledge about the pulmonary hypertension due to lung diseases or hypoxia. |
| PubMedID- 23920210 | Background: pulmonary hypertension is frequently associated with parenchymal lung disease. |
| PubMedID- 20092992 | pulmonary hypertension in lung diseases: survey of beliefs and practice patterns. |
| PubMedID- 20522579 | pulmonary hypertension (ph) associated with parenchymal lung diseases is one of the most common forms of ph. |
| PubMedID- 20920139 | The use of sildenafil to treat pulmonary hypertension associated with interstitial lung disease. |
| PubMedID- 21613438 | Purpose: to study the reliability of pulmonary vascular measurements based on computed tomography (ct) in the prediction of pulmonary hypertension (ph) in patients with advanced interstitial lung disease (ild) compared with those without ild. |
| PubMedID- 25183617 | We report the case of a 75-years-old man who diagnosed with severe pulmonary hypertension, associated with interstitial lung disease characterized by a rapid and fatal outcome. |
| PubMedID- 22958673 | Patients with lung diseases associated with pre-existing pulmonary hypertension (mean pap > 25 mm hg at rest) are advised against high altitude travel. |
| PubMedID- 24697923 | Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with pde-5 inhibitors. |
| PubMedID- 21182801 | In general, the severity of pulmonary hypertension due to lung diseases and/or hypoxia is usually from mild to moderate compared with pah [4,10]. |
| PubMedID- 22415303 | Little is known regarding the cellular and molecular mechanisms that lead to pulmonary hypertension in patients with interstitial lung disease, and effective treatment options are lacking. |
| PubMedID- 21536179 | Therapy specific for pulmonary arterial hypertension, poorly evaluated in pulmonary hypertension associated with infiltrative lung diseases, is occasionally proposed to patients with disproportionate pulmonary hypertension (mean pap > 35 mmhg), with often limited efficacy, and requiring careful follow-up (risk of increased hypoxemia) and invasive evaluation. |
| PubMedID- 21474572 | Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. |
| PubMedID- 25046428 | pulmonary hypertension associated with chronic obstructive lung disease and idiopathic pulmonary fibrosis. |
| PubMedID- 21538327 | Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. |
| PubMedID- 23009908 | pulmonary hypertension in the setting of parenchymal lung disease and conditions associated with chronic hypoxemia is commonly encountered in clinical practice and may adversely affect patients' function and mortality. |
| PubMedID- 23354416 | pulmonary hypertension is often associated with inflammatory lung diseases, for example chronic obstructive pulmonary disease, or autoimmune diseases. |
| PubMedID- 21266048 | Background: chronic alveolar hypoxia, due to residence at high altitude or chronic obstructive lung diseases, leads to pulmonary hypertension, which may be further complicated by right heart failure, increasing morbidity and mortality. |
| PubMedID- 21941650 | Signs of chronic heart disease, pulmonary fibrosis, or emphysema suggest that patients may have pulmonary venous hypertension or pulmonary hypertension associated with chronic lung disease rather than pah. |
| PubMedID- 25006405 | Tada-phild (tadalafil for pulmonary hypertension associated with chronic obstructive lung disease) is the first sufficiently powered randomized clinical trial testing the effect of pde-5i on key clinical and drug safety outcome measures in patients with at least moderate ph due to copd. |
| PubMedID- 26029619 | Some patients with group 3 pulmonary hypertension (ph) (ph due to lung disease and/or hypoxia) exhibit disproportionately advanced or "out-of-proportion" ph. |
| PubMedID- 21693294 | Effect of pulmonary hypertension in patients with end-stage lung disease on posttransplantation outcomes. |
| PubMedID- 24027689 | In recent years, the use of ino for “off-label” indications, such as for rescue treatment of preterm infants with severe respiratory failure, babies with severe chronic lung disease complicated by pulmonary hypertension and for prevention of bronchopulmonary dysplasia (bpd) has increased greatly. |
| PubMedID- 23841910 | Severe obstructive lung disease with pulmonary hypertension may be a contraindication for lung flooding. |
| PubMedID- 21181642 | [pulmonary hypertension due to chronic lung disease. |
| PubMedID- 26293503 | pulmonary hypertension (ph) due to lung disease (world health organization (who) group 3) is common, but severe ph, arbitrarily defined as mean pulmonary artery pressure >/=35 mmhg is reported in only a small proportion. |
| PubMedID- 25025352 | pulmonary hypertension due to fibrotic lung disease: hidden value in a neutral trial. |
| PubMedID- 25378843 | [25] the prevalence of isolated pulmonary arterial hypertension and pulmonary hypertension with interstitial lung disease in systemic sclerosis were similar and ranged between 18 and 22% in various studies. |
| PubMedID- 22936711 | We assessed the safety, tolerability and preliminary efficacy of riociguat, a soluble guanylate cyclase stimulator, in patients with pulmonary hypertension associated with interstitial lung disease (ph-ild). |
| PubMedID- 22034605 | [30] patients with pulmonary hypertension associated with underlying lung diseases such as chronic obstructive pulmonary disease (copd), pulmonary fibrosis, and sarcoidosis, also are at increased risk of mortality,[31–38] and those with combined emphysema, interstitial lung disease and pulmonary hypertension have a particularly high mortality risk, with only a 60% one-year survival. |
| PubMedID- 23797369 | We tested whether sscpah or systemic sclerosis-related pulmonary hypertension with interstitial lung disease imposes a greater pulmonary vascular load than ipah and leads to worse rv contractile function. |
| PubMedID- 24267299 | pulmonary hypertension due to lung disease and/or hypoxia. |
| PubMedID- 26473476 | However, our study could not adjust for pulmonary hypertension, a complication of interstitial lung disease, including idiopathic lung fibrosis. |
| PubMedID- 26166793 | pulmonary hypertension in the course of diffuse parenchymal lung diseases - state of art and future considerations. |
| PubMedID- 23884296 | Pulmonary arterial hypertension, pulmonary hypertension due to lung disease, or chronic thromboembolic pulmonary hypertension; phpvd), from those with left heart disease associated pulmonary hypertension (pulmonary venous hypertension; pvh) is crucial as workup and treatment options differ dramatically. |
Page: 1 2